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Abstract  
Introduction: The Cervical Cancer (CC) is one of the heavy and costly diseases for the population and the health system. We want to know 
through this study, the first in Morocco, the annual cost of the treatment of this disease at the National Institute of Oncology (NIO) in Rabat, we 
also want to explore the possibility of flat-rate management of this disease in order to standardize medical practices and improve reimbursement 
by health insurance funds. Methods: 550 patients were treated for their cervical cancer in the Rabat's NIO. Data of all of medical and surgical 
services offered to patients were collected from the NIO registry. The cost of care was assessed using the method of micro-costing. We will focus 
to the total direct cost of all the services lavished to patients in NIO. Results: The global cost was about US$ 1,429,673 with an average 
estimated at US$ 2,599 ± US$ 839. Radiotherapy accounts for 55% of total costs, followed by brachytherapy (27%) and surgery (7%). This three 
services plus chemotherapy influence the overall cost of care (p <0.001). Other services (radiology, laboratory tests and consultations) represent 
only 10%. The overall cost is influenced by the stage of the disease, this cost decreased significantly evolving in the stage of CC (p <0.001). 
Conclusion: The standardization of medical practices is essential to the equity and efficiency in access to care. The flat-rate or lump sum by stage 
of disease is possible and interesting for standardizing medical practices and improving the services of the health insurance plan. 
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Cervical Cancer (CC) is one of the important public health problems. 
It is estimated that over a million women worldwide currently have 
cervical cancer. Most of these women are not diagnosed, and they 
have no access to treatment that could cure them or prolong their 
survival [1]. In women, CC, the second most common cancer in 
developing regions (452,000 cases), is only the 10th most common 
cancer in developed regions (76,000 cases) [2]. Cervical cancer is 
the fourth most common cancer in women, and the seventh overall, 
with an estimated 528,000 new cases in 2012. As with liver cancer, 
a large majority (around 85%) of the global burden occurs in the 
less developed regions, where it accounts for almost 12% of all 
female cancers. There were an estimated 266,000 deaths from 
cervical cancer worldwide in 2012, accounting for 7.5% of all female 
cancer deaths. Almost nine out of ten (87%) cervical cancer deaths 
occur in the less developed regions [3]. The 14 million estimated 
new cases of cancer worldwide annually inflict a crushing burden of 
economic costs and human suffering [4,5]. The estimated total 
annual economic cost of cancer was approximately US$ 1.16 trillion 
in 2010, the equivalent of more than 2% of total global gross 
domestic product [6]. Between 2.4 million and 3.7 million avoidable 
deaths per year, 80% of which occur in low and middle-income 
countries [6]. A reasonable estimate shows that the world could 
have saved between US$ 100 billion and US$ 200 billion in 2010 by 
investing in prevention, early detection, and effective treatment of 
cancer [6]. A 90% reduction in cases through prevention implies a 
reduction of at least 20% in the total estimated costs of treating 
cancer or approximately US$ 65 billion per year [7]. CC is by far the 
most common Human Papillomavirus (HPV)-related disease [8]. The 
number of new genital HPV infections worldwide is estimated at 30 
million per year. It is estimated that 50 to 75% of women aged 15 
to 44 are or have been exposed to HPV [9,10]. Because the 
vaccines do not protect against all HPV types that can cause cervical 
cancer, girls vaccinated against HPV will still require CC screening 
later in their lives [1]. But in developing countries, limited access to 
effective screening explains that the disease is often diagnosed at a 
more advanced stage. The high mortality rate from cervical cancer 
globally (52%) could be reduced by effective screening and 
treatment programs [8]. The most cost-effective strategies were 
those that required the fewest visits, resulting in improved follow-up 
testing and treatment. Screening women once in their lifetime, at 
the age of 35 years, with a one-visit or two-visit screening strategy 
involving visual inspection of the cervix with acetic acid or DNA 
testing for HPV in cervical cell samples, reduced the lifetime risk of 
cancer by approximately 25 to 36%, and cost less than $500 per 
year of life saved. Relative cancer risk declined by an additional 
40% with two screenings (at 35 and 40 years of age), resulting in a 
cost per year of life saved that was less than each country's per 
capita gross domestic product a very cost-effective result[11]. In 
Morocco, the Rabat cancer registry shows that 2,473 new cases of 
cancer were registered among residents in this city during the 
period 2006-2008. The overall world age-standardized rate (ASR) 
for all sites combined was 136.6/100,000 for men and 
114.5/100,000 for women. In females, the most frequently reported 
malignancies were breast cancer (39.9%), followed by CC (11.4%), 
colorectal cancer (7.5%), Non-Hodgkin Lymphoma (NHL) (3.4%), 
and thyroid cancer (3.4%) [12]. We want to study, through this 
work, the annual cost of the treatment of this disease at the 
National Institute of Oncology (NIO) in Rabat. We also want to 
explore the possibility of flat-rate management of this disease in 
order to standardize medical practices and improve reimbursement 





550 patients followed retrospectively for their CC in the Rabat's NIO 
for one year, between first January and 31 December 2006, were 
included in this study. The analyzed data were extracted from the 
register of the Epidemiology Unit of Rabat's NIO. Patients received 
various services: surgery, radiotherapy, brachytherapy and 
chemotherapy. They have also undergone biological analyzes, 
anatomopathology analysis and radiological examinations. All these 
services, summarized in Table 1 [13], will be integrated into the 
analysis of the cost of the CC. Data of all medical and surgical 
services offered to patients were collected from the NIO registry. 
The unit and overall cost of care was assessed using the method of 
micro-costing. We will focus to the total direct cost of all the 
services lavished to patients in the NIO in Rabat. The calculation of 
the cost of services provided in this study was done between 
November 2012 and November 2013. The cost was measured in 
two ways: •The overall cost of care based on the relative costs of 
each service, •The overall cost based on the lump sum of the 
system of mandatory health insurance established in the 
agreements signed between the health insurance funds and the 
University Hospitals. Statistical analysis: Statistical analyses were 





The average age of patients was 50.72 ± 11.76 years with a 
predominance of the age group between 45 and 54 years (32%) 
followed by those between 35 and 44 years (26%) and those 
between 55 and 64 years (21%). The most common stage in our 
series is the IIb stage (37.6%) followed by IIIb (36%). IVa and IVb 
stages represent a very small proportion in our series (2.5%). 
Regional cancer is the most type of cervical cancer in our series 
(410 patients, 74.5%) followed by local cancer (126 patients, 
22.9%) and distant cancer (14 patients, 2.5%). Localized cancer 
denotes the classification of invasive cervical cancer as stage Ia1, 
Ia2, Ib1, Ib2, or IIa, regional locally advanced as stage IIb, IIIa, or 
IIIb, and distant as stage IVa or IVb. The total cost of treatment of 
550 patients has been estimated at $1,429,673 with an average 
estimated at US$ 2,599 ± US$ 839 (1$ US = 9 Moroccan dirham). 
Radiotherapy alone accounts for 53% of total cost, followed by 
brachytherapy (27%) and surgery (14%). The three services 
represent 94% of the overall cost of care of the CC at Rabat's NIO. 
Other services (chemotherapy, radiological examinations, laboratory 
tests, consultations) represent only the remaining 6%. The overall 
cost of managing patients depends significantly on the stage of the 
CC (Table 2), the cost decreases with the stage of the disease; (r = 
-0.491, p <0.001). This is mainly due to the limitation of the 
therapeutic choices for advanced cases (distant). In addition, there 
is a significant correlation between age and cancer stage (p = 
0.002). This could be explained by the late diagnosis and late 
management in some women. On the other hand, the overall cost 
depends mainly for four services, radiotherapy, brachytherapy, 
surgery and chemotherapy (p <0.001). These services must be 
taken into account when setting the flat-rate of managing patients 
by CC stage. For the rest of the services, that is to say, radiology, 
biological tests, anatomopathology and others, they do not influence 
the overall cost, so it can be standardized in all patients at any 
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Discussion 
 
We have analyzed a large number of published studies on the cost 
of CC, few have addressed the cost of treatment and management 
of patients and most have focused on the cost-effectiveness of 
diagnostic or vaccination but there are fewer published studies that 
assess screening and vaccination in developing countries. M. E. van 
den Akker-van Marle et al have demonstrated through the analysis 
of 500 screening policies that there were 15 efficient screening 
policies. For the efficient policies, the predicted gain in life 
expectancy ranged from 11.6 to 32.4 days, compared with a gain of 
46 days if cervical cancer mortality were eliminated entirely. The 
average cost-effectiveness ratios increased from US$ 6,700 (for the 
longest screening interval) to US$ 23,900 per life-year gained. They 
concluded that the basis for the diversity in the screening policies 
among high-income countries does not appear to relate to the 
screening policies' cost-effectiveness ratios, which are highly 
sensitive to the number of Pap smears offered during a lifetime 
[14]. Van Rosmalen et al have demonstrated that under the base-
case assumptions, primary HPV testing with cytology triage is the 
most cost effective strategy. Using cost-effectiveness thresholds of 
US€ 20,000 and US€ 50,000 per Quality-Adjusted Life-Year (QALY) 
gained yields optimal screening programs with three and seven 
screening rounds, respectively [15]. On the evaluation of the cost-
effectiveness of the vaccine against HPV, Jane J. Kim et al have 
demonstrated that the cost-effectiveness ratio of vaccination of 12-
year-old girls in USA was US$ 43,600 per QALY gained, as 
compared with the current screening practice. Under baseline 
assumptions, the cost-effectiveness ratio for extending a temporary 
catch-up program for girls to 18 years of age was US$ 97,300 per 
QALY; the cost of extending vaccination of girls and women to the 
age of 21 years was US$ 120,400 per QALY, and the cost for 
extension to the age of 26 years was US$ 152,700 per QALY [16]. 
They concluded that the cost-effectiveness of HPV vaccination will 
depend on the duration of vaccine immunity and will be optimized 
by achieving high coverage in preadolescent girls, targeting initial 
catch-up efforts to women up to 18 or 21 years of age, and revising 
screening policies [16]. In Canada, Anonychuk et al found that 
vaccination was estimated to cost $18,672-$31,687 per QALY-
gained, the lower range representing inclusion of cross protective 
efficacy and herd immunity [17]. They concluded that in the context 
of current screening patterns, vaccination of 12-year old Canadian 
females with a cervical cancer vaccine is estimated to significantly 
reduce cervical cancer and mortality, and is a cost-effective option. 
However, the economic attractiveness of vaccination is impacted by 
the vaccine´s duration of protection and the discount rate used in 
the analysis [17]. In our context, the importance of assessing the 
overall cost of the treatment of cancer in developing countries is to 
assess the overall budget for the monitoring and treatment of 
patients in accordance with international standards. Once the 
budget is known, the hospital asked the financial resources of the 
ministry of health or NGOs that allow it to provide the necessary 
patient care (radiotherapy, brachytherapy, surgery and 
chemotherapy) while ensuring efficiency and equity in access to 
care. 
  
In addition, the flat-rate or sum lump has the advantage of offering 
patients who are classified in the same stage of disease the same 
quality care regardless of their health insurance plan or socio-
economic level. This is, unfortunately, not always guaranteed in 
countries with limited economic means. In our case, the fact that 
radiation is the most significant burden could be explained by 
important elements: cost or package radiotherapy representing on 
average 50% of total costs and the frequency of this act in our 
series (94%). The same observation could be registered for 
brachytherapy but its frequency was lower than radiotherapy. As for 
the surgery, and despite the high cost of the latter, its frequency 
was low in our series compared to the two previous services, it was 
made for only 23% of patients followed. The cost of care is affected 
by stages of cancer. Referring to the results of our study, the 
standard deviations from the average costs are lower for stage IVA 
and IVB. In the early stages, ie IB1, IIA, IIB and III, standard 
deviations are significant and important work to standardize medical 
practices should be undertaken within the NIO. In addition, the low 
cost of anticancer drugs (cisplatin and fluoro-uracil) and 
chemotherapy protocols proposed in the management of the CC at 
NIO has significantly reduced the impact of this act on the overall 
cost of care. Otherwise, the flat-rate to manage CC will no doubt 
bring substantial benefits to the hospital structure: 
 
Standardization of medical practices: As concluded in our 
work, a package could be applied by stage of CC. In this case, care 
providers will be encouraged to follow the protocols set up by the 
working groups without a concern about the overall amount of 
support or funding capacity of patients. The most important is that 
patients benefit from optimal management according to current 
guidelines (Table 3). 
 
Management of information's flow and patients: an integrated 
information system, or lack of it a system of record management 
and medical records would be an asset and an advantage of the 
flat-rate of support CC. The mastery of medical, administrative and 
financial information are easier with fixed flat-rate instead of 
adopting a plethora of database according to the stages of the 
disease, the social level of the patient and the health insurance 
funds which they are affiliated. Once the flat-rate is fixed between 
the health insurance funds and hospitals, insurance funds could pay 
the hospital depending on the stage of the cancer (local, regional or 
distant) and the number of patients. We made an evaluation of the 
overall cost of care based on international standards. The result of 
this work is summarized in the table below: Health insurance plan: 
Reimbursement of a flat-rate or a lump sum has advantages but 
also can cause loss of information on services really provided by 
health care providers or hospitals. However, and taking into 
account, on the one hand, the large flow records management and 
reimbursement that flood the health insurance funds, and secondly 
the lack of staff processing and controlling of these records, the flat-
rate support for the CC stage could be a solution to improve fund 





The CC is one of the most common cancers in women and deadly. 
The management of this type of pathology firstly requires optimal 
access of women to prevention and early diagnosis, and later to the 
appropriate therapeutic measures depending on the stage of 
disease and socioeconomic level the patient. In developing countries 
where about 90% of all cervical cancer deaths occur, we assist to a 
public health failure because infrastructure and technological 
expertise for cytology programs are not available and three visits for 
screening, diagnosis, and treatment are not feasible. For countries 
with limited resources, screening efforts should target women age 
35 or older, and efforts should focus on attaining high coverage of 
single lifetime screening before increasing the frequency of 
screening. 
 
What is known about this topic 
 
• CC is one of the important public health problems (It is 
the fourth most common cancer in women and the 
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seventh overall with an estimated 528,000 new cases in 
2012); 
• The cost of care of cervical cancer is very important, and 
many middle-income countries cannot cover the needs of 
all women who suffer from this cancer; 
• Early detection of cancer in the early stages can prevent 
many deaths and make big savings. 
 
What this study adds 
 
• The results of this study demonstrate that the cost of care 
is affected by stages of cancer ie the cost decreases with 
the stage of the disease. This is mainly due to the 
limitation of the therapeutic choices for advanced cases 
(distant); 
• Referring to the results of our study, the standard 
deviations from the average costs are lower for stage IVA 
and IVB but in the early stages, ie IB1, IIA, IIB and III, 
standard deviations are significant and important work to 
standardize medical practices should be undertaken within 
the NIO; 
• When a sum lump can be applied by stage of CC, care 
providers will be encouraged to follow the protocols set 
up by the working groups without a concern about the 
overall amount of support or funding capacity of patients. 
In this case, the most important is that patients benefit 
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Table 1: summary of services lavished on 550 patients with CC 
Services Number Percentage (%) 
Biological analyzes 
  
Blood count 428 66.21 







Thoracic radiography 480 87.3 
abdominopelvic ultrasound 44 8 
Abdominopelvic CT 501 91 
MRI 17 3 
Colposcopy and biopsy 
  
Biopsy 550 100 
Surgery 
  
Total Colpohysterectomy plus lymphadenectomy 96 17.4 
Total Colpohysterectomy without lymphadenectomy 19 3.4 
Total hysterectomy interadnexal 1 0.2 
Colpectomy 2 0.4 
NP 1 0.2 
Radiotherapy 
  
Pelvis 505 92 
Pelvis and Para-aortic lymphadenopathy 10 1.80 
Brachytherapy 
  
Utero-vaginal 395 72 
Low Dose Rate 334 61 
High Dise Rate 61 11 
Chemotherapy 
  
Concomitant 422 76.90 
Neoadjuvant 21 3.80 
Adjuvant 2 0.40 




Table 2: average, minimum and maximum cost of CC by type of cancer 




Local 126 3,093.9 1,215.2 934.4 5,938.0 
Regional 410 2,473.8 614.2 934.4 5,652.4 




Table 3: minimum and maximum cost of CC by type of cancer (based on the international standards) 
Stage Minimum Maximum 
Local 1 218.9 5 270.2 
Regional 5 270.2 6 981.3 
Distant 552.2 6 981.3 
 
 
 
